Self-consumption: the interplay of autophagy and apoptosis | Nature Reviews Molecular Cell Biology | 2014 | 1.4K |
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | Lancet Oncology, The | 2014 | 982 |
Effects of long-term exposure to air pollution on natural-cause mortality: an analysis of 22 European cohorts within the multicentre ESCAPE project | Lancet, The | 2014 | 838 |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study | Lancet Oncology, The | 2014 | 753 |
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma | Nature | 2014 | 550 |
Integrated genomic characterization of adrenocortical carcinoma | Nature Genetics | 2014 | 423 |
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas | Nature Genetics | 2014 | 413 |
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet Oncology, The | 2014 | 359 |
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer | Journal of Clinical Oncology | 2014 | 322 |
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study | Journal of Clinical Oncology | 2014 | 314 |
A dual role for autophagy in a murine model of lung cancer | Nature Communications | 2014 | 296 |
NEAT1 long noncoding RNA regulates transcription via protein sequestration within subnuclear bodies | Molecular Biology of the Cell | 2014 | 292 |
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma | Journal of Clinical Oncology | 2014 | 290 |
Molecular mechanisms of ATP secretion during immunogenic cell death | Cell Death and Differentiation | 2014 | 283 |
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial | Lancet Oncology, The | 2014 | 283 |
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) | Lancet Oncology, The | 2014 | 282 |
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study | Annals of Oncology | 2014 | 267 |
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2014 | 264 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial | Lancet Oncology, The | 2014 | 229 |
Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer | Nature Genetics | 2014 | 228 |
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer | Nature Genetics | 2014 | 226 |
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial | Lancet Oncology, The | 2014 | 215 |
Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size | European Radiology | 2014 | 206 |
Definition and management of radioactive iodine-refractory differentiated thyroid cancer | Lancet Diabetes and Endocrinology,the | 2014 | 194 |
Nucleocytosolic depletion of the energy metabolite acetyl-coenzyme a stimulates autophagy and prolongs lifespan | Cell Metabolism | 2014 | 189 |